Betula pendula pollen allergen (Bet v)

Betula pendula pollen allergens, specifically the major allergen Bet v 1, are the primary environmental triggers for seasonal allergic rhinitis (hay fever) and conjunctivitis in temperate regions of the Northern Hemisphere [1, 9, 13]. Bet v 1 is a member of the pathogenesis-related protein family 10 (PR-10), which functions in plants as a defense protein against biotic and abiotic stressors [2, 13]. In sensitized humans, these allergens bind to specific IgE antibodies on mast cells and basophils, triggering the release of inflammatory mediators and activating T-cell responses [9, 17]. These allergens are also highly cross-reactive with homologs in other trees and various plant-derived foods, often leading to Oral Allergy Syndrome [9, 14]. Clinically, Betula pendula pollen allergens serve as the therapeutic target for allergen immunotherapy (AIT), which aims to modify the underlying immune response to induce long-term tolerance [1, 3, 5]. Targeted drugs like Itulazax utilize standardized allergen extracts to desensitize the immune system by shifting the response from a Th2-mediated allergic state to a state of peripheral T-cell tolerance characterized by the production of blocking IgG4 antibodies [8, 10, 17]. Management of these allergens via immunotherapy requires careful clinical supervision due to the inherent risk of systemic allergic reactions or anaphylaxis upon exposure [3, 10].

Other names

Birch pollen allergensBetula verrucosa pollen allergensSilver birch pollen allergensWhite birch pollen allergensBet v 1Bet v allergen

Allergen immunotherapy (AIT) involving the induction of immunological tolerance through regulatory T-cell activation, desensitization of Th2 cells, and the production of allergen-specific IgG4 blocking antibodies